NASDAQ · Medical - Diagnostics & Research

CDNA (CDNA) Stock

$43.71 +14.72% NASDAQ: CDNA Healthcare

Valuation

MetricValue
Price$43.71
Market Cap$2.26B
P/E Ratio18.87
P/B Ratio3.50
P/S Ratio2.68
EPS (TTM)$0.00
52-Week High$43.71
52-Week Low$10.96
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-2.37%
ROA-1.80%
ROCE-6.93%
Gross Margin68.56%
Operating Margin-3.20%
Net Margin-1.98%
Debt/Equity0.06
Current Ratio2.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$296.0M$322.0M$280.0M$334.0M$380.0M
Operating Profit$-30.0M$-77.0M$-203.0M$41.0M$-21.0M
Net Profit$-31.0M$-77.0M$-190.0M$53.0M$-21.0M
EPS$-0.59$-1.44$-3.54$0.93$-0.40
Op Margin-10.0%-24.0%-72.5%12.2%-5.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$567.0M$543.0M$467.0M$491.0M$413.0M
Total Liabilities$101.0M$112.0M$205.0M$113.0M$110.0M
Cash$348.0M$90.0M$82.0M$115.0M$65.0M
Borrowings$21.0M$39.0M$34.0M$28.0M$20.0M

Latest News

CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology Exec Edge · Jul 2, 2026 CareDx Closes Naveris Acquisition MT Newswires · Jul 1, 2026 CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology Business Wire · Jul 1, 2026 Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division GlobeNewswire · Jul 1, 2026 CareDx Closes Sale of Lab Products Business to Eurobio Scientific MT Newswires · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-25.0M$-18.0M$38.0M$42.0M
Investing Cash Flow$27.0M$-253.0M$31.0M$-7.0M$-4.0M
Financing Cash Flow$-3.0M$-5.0M$-30.0M$-6.0M$-101.0M
Net Cash Flow$214.0M$-258.0M$-8.0M$32.0M$-49.0M
Free Cash Flow$-40.0M$-50.0M$-28.0M$32.0M$36.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA407.10
FCF Yield5.90%
Quick Ratio3.07
Interest Coverage—
Return 1Y190.17%
Return 3Y255.41%
Return 5Y-55.81%

Ownership

Insiders Held3.42%
Institutions Held101.73%
Institutions Float Held105.33%
Institutional HolderSharesReport Date
Blackrock Inc.4,522,0962026-03-31
BAMCO Inc.3,336,4092026-03-31
State Street Corporation2,760,3852026-03-31
ARK Investment Management, LLC2,227,5562026-03-31
Deerfield Management Company, L.P2,191,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CRMD $7.33 +1.88% 3.94 $574.66M 0.00%
CSTL $24.44 -0.99% -23.63 $741.26M 0.00%
DRIO $7.47 -4.11% -10.51 $54.62M 0.00%
EMBCEmbecta Corp. $3.46 +5.17% 1.72 $205.27M 1.22%
EVH $3.04 -4.56% -0.77 $341.38M 0.00%

About CDNA

CDNA is led by CEO John Walter Hanna Jr., employs 644 people, headquartered in US, publicly traded since 2014.

CDNA stock trades at $43.71 with a market capitalization of $2.26B. The stock is valued at a price-to-earnings (P/E) ratio of 18.87, price-to-book of 3.50, price-to-sales of 2.68. Over the past 52 weeks the stock has ranged between $10.96 and $43.71, and currently trades at its 52-week high.

On profitability, CDNA generates a return on equity (ROE) of -2.37%, return on capital employed of -6.93%, an operating margin of -3.20%, a net profit margin of -1.98%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides